| Ytd | 16.94% | |
| 1y | 331.68% |
| Open | 93.41 | Prev Close | 93.11 | Low | 90.97 | High | 94.14 | Mkt Cap | 1.36B |
| Vol | 352.30K | Avg Vol | 339.10K | EPS | -8.39 | P/E | -11.01 | Forward P/E | -14.78 |
| Beta | 3.52 | Short Ratio | 9.33 | Inst. Own | 89.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 90.94 | 200-d Avg | 85.28 | 1yr Est | 277.50 |
INBX News
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 a
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nas
Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investo
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, O
SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "
Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is report
Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combinati
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (
– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNews
Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates a
Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs
Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experime
U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares
Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA a
SAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the
– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT – SAN DIEGO, April 20, 2026 /
Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) has received a consensus rating of "Hold"
SG Americas Securities LLC acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) in th
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - G
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the
Dynamic Technology Lab Private Ltd bought a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX)
Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading streng
Gainers
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 422 stocks made new 52-week lows.
During the Thursday's session, 100 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched
Friday's session saw 466 companies set new 52-week highs.
During Thursday's morning session, 316 companies made new 52-week highs.
On Tuesday morning, 113 companies hit new 52-week highs.